Beltran Lab

You are here


Found 69 results
Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y et al..  2013.  Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.. Neoplasia. 15(7):761-72.
Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P et al..  2013.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.. Nat Biotechnol. 31(11):1023-31.
Beltran H.  2013.  DNA mismatch repair in prostate cancer.. J Clin Oncol. 31(14):1782-4.
Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..  2013.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.
Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O.  2013.  Epigenomic alterations in localized and advanced prostate cancer.. Neoplasia. 15(4):373-83.
Beltran H, Rubin MA.  2013.  New strategies in prostate cancer: translating genomics into the clinic.. Clin Cancer Res. 19(3):517-23.
Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.
Beltran H, Yelensky R, Frampton GM, Park K, , MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al..  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. Eur Urol. 63(5):920-6.
Beltran H, Park K, Tagawa ST, Macdonald T, Nanus DM, Mosquera JMiguel, Rubin MA.  2012.  Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. J Clin Oncol. 30(5_suppl):120.
Beltran H, Tagawa ST, Park K, Macdonald T, Milowsky MI, Mosquera JMiguel, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):e386-9.
Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):386-9.
Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH et al..  2012.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.. J Pathol. 227(3):286-97.
Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.
Beltran H, Park K, Tagawa ST, Yelensky R, Lipson D, Frampton G, Stephens PJ, Cronin MT, Nanus DM, Mosquera JMiguel et al..  2012.  Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. J Clin Oncol. 30(5_suppl):110.
Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH et al..  2012.  Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.. Mol Cancer Ther. 11(3):775-83.
Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.  2012.  Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).. BJU Int. 109(7):968-85.